The PureVu colon preparation system cost saving in the USA

Abstract

The use of the PureVu system to clean inadequately-prepared colons prior to colonoscopy could save the US healthcare system between $US3.1 to $3.7 billion and reduce the incidence of colorectal cancer (CRC) due to missed diagnoses, according to a study published in Cost Effectiveness Resource Allocation.The authors developed a lifetime Markov model for 60-year-old patients at average risk of CRC who would undergo 10-year colonoscopies as part of their care. Four scenarios were examined: Medicare patients with and without PureVu, and private payer patients with and without PureVu. Clinical and QOL inputs were taken from peer-reviewed literature. Direct costs (2019 values) included diagnostic colonoscopies with and without removal of polyps/ adenomas, colonoscopy complications, physician visits and cancer treatment. Cost sources included Medicare fee schedules, published literature and private reimbursement rates. Future costs and quality-adjusted life years (QALYs) were discounted by 3%. Base-case analyses used a price of $750 for PureVu, and assumed 60% colonoscopy compliance and an inadequate prep rate of 25% for standard care and 5% for PureVu.In the base case, PureVu was less costly and resulted in greater QALYs compared with standard care for both Medicare ($6070 and 15.25 QALYs vs $6903 and 15.10 QALYs, respectively) and private paying patients ($8216 and 15.25 vs $9208 and 15.10, respectively). PureVu was also associated with a 1.1% lower absolute CRC incidence rate than standard care for early cases and a 0.2% lower absolute rate for advanced cases.